Haleon PLC (HLNCF)
4.708
-0.07
(-1.40%)
USD |
OTCM |
Dec 13, 16:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 42.57B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 18.38% |
Valuation | |
PE Ratio | 27.83 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 3.036 |
Price to Book Value | 2.028 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | 0.0256 |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.5263 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | -- |
Profile
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition. |
URL | https://www.haleon.com |
Investor Relations URL | N/A |
HQ State/Province | N/A |
Sector | Consumer Staples |
Industry | Personal Care Products |
Equity Style | Large Cap/Blend |
Next Earnings Release | Feb. 28, 2025 (est.) |
Last Earnings Release | Jul. 08, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Aug. 15, 2024 |
Ratings
Profile
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition. |
URL | https://www.haleon.com |
Investor Relations URL | N/A |
HQ State/Province | N/A |
Sector | Consumer Staples |
Industry | Personal Care Products |
Equity Style | Large Cap/Blend |
Next Earnings Release | Feb. 28, 2025 (est.) |
Last Earnings Release | Jul. 08, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Aug. 15, 2024 |